Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

BACKGROUND Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS We analyzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melanoma who had had an initial objective tumor regression in response to anti-PD-1 therapy (pembrolizumab) followed by disease progression months to years later. RESULTS Whole-exome sequencing detected clonal selection and outgrowth of the acquired resistant tumors and, in two of the four patients, revealed resistance-associated loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele. A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative effects on cancer cells. The B2M truncating mutation led to loss of surface expression of major histocompatibility complex class I. CONCLUSIONS In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.).

[1]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[2]  A. Ribas,et al.  Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. , 2015, European journal of cancer.

[3]  A. Ribas Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[4]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. , 2015, The Journal of clinical investigation.

[5]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[6]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[8]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[9]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[10]  M. Kloor,et al.  Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression , 2014, Clinical Cancer Research.

[11]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[12]  L. Platanias,et al.  Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes , 2014, Molecular Cancer Research.

[13]  Antoni Ribas,et al.  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.

[14]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[15]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[16]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[17]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[18]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[19]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[21]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[22]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[23]  R. Schreiber,et al.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.

[24]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[25]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[26]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[27]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[28]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[29]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[30]  G. Stark,et al.  Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-& gamma; signal transduction pathway , 1993, Nature.

[31]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[32]  T. Gajewski,et al.  Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. , 2016, Cytokine.

[33]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[34]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[35]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[36]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[38]  C. Schindler,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. , 1993, Nature.

[39]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.